Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis

Cancer Research

Volumn 57, Issue 3, 1997, Pages 362-365

  Jansen, Burkhard ^a,b   Schlagbauer Wadl, Hermine ^a,b   Eichler, Hans Georg ^a   Wolff, Klaus ^b   Van Elsas, Andrea ^c   Schrier, Peter I ^c   Pehamberger, Hubert ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Division of General Dermatology   (Austria)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DIAGNOSIS; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CISPLATIN; DRUG RESISTANCE; FEMALE; GENES, RAS; HUMANS; MELANOMA; MICE; MICE, SCID; POINT MUTATION; TUMOR CELLS, CULTURED;

EID: 0031059608     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. van Elsas, A., Zerp, S., van der Flier, S., Krüse, M., Aarnoudse, C., Hayward, N., Ruiter, D., and Schrier, P. I. Relevance of UV-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol., 149: 883-893, 1996.
2. Jansen, B., Inoue, S. A., Wadl, H., Eichler, H-G., Wolff, K., van Elsas, A., Schrier, P. I., and Pehamberger, H. N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse models. Int. J. Cancer, 67: 821-825, 1996.
3. Le Ruppert, K., Masters, J. R., Knuechel, R., Seegers, S., Trainsky, M. A., Hofstaedter, F., and Buettner, R. The effect of retinoic acid on chemosensitivity of PA-1 human teratocarcinoma cells and its modulation by an activated N-ras oncogene. Int. J. Cancer, 51: 646-651, 1992.
4. Peters, G. J., Wets, M., Keepers, Y. P. A. M., Oskam, R., van Arkotte, J., Noordhuis, P., Smid, K., and Pinedo, H. M. Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer, 54: 450-455, 1993.
5. Wani, M. A., Xu, X., and Stambrook, P. J. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Cancer Res., 54: 2504-2508, 1994.
6. +-ATPase activity and cisplatin sensitivity between transformants induced by U-ras and those induced by K-ras. Int. J. Cancer, 58: 672-677, 1994.
7. Basu, A., and Cline, J. S. Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int. J. Cancer, 63: 597-603, 1995.
8. Sanchez-Prieto, R., Vargas, J. A., Carnero, A., Marchetti, E., Romero, J., Durantez, A., Lacal, J. C., and Ramon Y Cajal, S. Modulation of cellular chemoresistance in keratinocytes by activation of different oncogencs. Int. J. Cancer, 60: 235-243, 1995.
9. Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J., and Giaccia, A. J. Modulation of c-Myc activity and apoptosis in vivo. Cancer Res., 56: 4315-4319, 1996.
10. Chu, G. Cellular responses to cisplatin. J. Biol. Chem., 269: 787-790, 1994.
11. Wagner, R. W. The state of the art in antisense research. Nat. Med., 1: 1116-1118, 1995.
12. Kashani-Sabet, M., Funato, T., Florenes, V. A., Fodstad, O., and Scanlon, K. J. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res., 54: 900-902, 1994.
13. Kohl, N. E., Mosser, S. D., De Solms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 260: 1934-1937, 1993.
14. James, G. L., Goldstein, J. L., Brown, M., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Marsters, J. C., Jr. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC), 260: 1937-1942, 1993.
15. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., De Solms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Kolban, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Nell, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
16. McClay, E. F., Albright, K. D., Jones, J. A., Christen, R. D., and Howell, S. B. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int. J. Cancer, 55: 1018-1022, 1993.
17. O'Dwyer, P. J., Moyer, J. D., Suffness, M., Harrison, S. D., Jr., Cysyk, R., Hamilton, T. C., and Plowman, J. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res., 54: 724-729, 1994.
18. Buzaid, A., Legha, S. S., Balch, C. M., Ros, M., Ring, S., Plager, C., Papadopoulos, N. E., El Naggar, A. K., and Benjamin, R. S. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer (Phila.), 74: 2476-2481, 1994.
19. Feliu, J., Gonzales-Baron, M., Chacon, J. I., Espinosa, E., Garrido, P., Castro, J., Escobar, Y., Colmenarejo, A., Garcia-Giron, C., Espinosa, J., and Ordonez, A. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. Cancer Chemother. Pharmacol., 38: 191-194, 1996.